



Annual Liver Cancer Virtual CME Conference
October 29, 2022
9:45 a.m. – 3:00 p.m. EST

At course completion, attendees should be able to: Increase Knowledge Understand the molecular classification of HCC Understand the multidisciplinary approach to management of HCC Competency Define the mechanisms that lead to the development of hepatocellular cancer (HCC) Performance Discuss the available evidence-based data on promising treatment options for advanced HCC Discuss the advances in research and development

Program Overview

The goal of this course module is to help clinicians and other service providers understand the management of Hepatocellular Carcinoma in the US population, innovations in therapies and advances in research and development.

Learning Objectives

At course completion, attendees should be able to:

Increase Knowledge

Understand the molecular classification of HCC
Understand the multidisciplinary approach to management of HCC

Competency

Define the mechanisms that lead to the development of hepatocellular cancer (HCC)

Performance

Discuss the available evidence-based data on promising treatment options for advanced HCC
Discuss the advances in research and development

Course Directors

Dulabh K Monga, MD
Associate Professor of Medicine
Drexel University School of Medicine
Allegheny Health Network Cancer Institute
Pittsburgh, PA

Satdarshan (Paul) Singh Monga, MD
UPMC Endowed Chair for Experimental Pathology
Professor of Pathology and Medicine
Director, Pittsburgh Liver Research Center,
Chief and Vice Chair, Division of Experimental Pathology
University of Pittsburgh, School of Medicine and UPMC
Pittsburgh, PA

Schedule

9:45 -10:00 a.m. Welcome and Overview

Dulabh K Monga, MD and Satdarshan (Paul) Monga, MD
Course Directors

Suzanna Masartis
CEO, Community Liver Alliance

10:00 a.m. How Does Liver Cancer Develop?

Satdarshan (Paul) Monga, MD
Professor and Vice Chair of Pathology
Director, Pittsburgh Liver Research Center
University of Pittsburgh and UPMC
Pittsburgh, PA

10:30 a.m. HCC Surveillance in High Risk Liver Cancer

Renumathy Dhanasekaran, MD
Assistant Professor, Division of Gastroenterology and Hepatology
Stanford University School of Medicine
Stanford, CA

11:00 a.m. Radiation Therapy for HCC

Paul Renz, DO
Radiation Oncology Specialist
Allegheny Health Network Cancer Institute
Pittsburgh, PA

11:30 a.m.

Role of Locoregional Therapies in HCC Management

Riad Salem, MD
Vice-Chair, Image-Guided Therapy
Chief, Interventional Radiology and Oncology
Department of Radiology
Feinberg School of Medicine
Northwestern University
Chicago, IL

12:00 p.m. BREAK/Exhibits

12:30 p.m. Role of Surgical Resection and Transplantation in HCC Management

Rachel Tindall, MD, FACS
Transplant Surgeon, Hepatobiliary & Pancreas Cancer
Allegheny Health Network
Pittsburgh, PA

1:00 p.m. Medical Management of HCC

Dulabh K Monga, MD
Associate Professor of Medicine
Drexel University School of Medicine
Allegheny Health Network Cancer Institute
Pittsburgh, PA

1:30 p.m. Molecular Pathology of Hepatobiliary Tumors

Aatur Singhi, MD, PhD
Assistant Professor of Pathology
University of Pittsburgh and UPMC
Pittsburgh, PA

2:00 p.m. Advances in the Management of Biliary Tract Cancers

Rachna Shroff, MD, MS
Associate Professor of Medicine
Chief, GI Medical Oncology
University of Arizona Cancer Center
Tucson, AZ

2:30 p.m. Palliative Care of Cancer Patients

Sidra Anwar, MD
Hospice & Palliative Medicine Specialist
Allegheny Health Network
Pittsburgh, PA

**3:00 p.m. Case Presentations/Q & A
Resectable/Transplantable HCC
Non-Resectable Non-Transplantable HCC and
Medical and Locoregional Options
Intrahepatic Cholangiocarcinoma**

Paul Renz, DO
Dulabh Monga, MD
Riad Salem, MD
Rachna Shroff, MD
Rachel Tindall, MD